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Background: First-line (1L) therapy with pembrolizumab in patients
with metastatic NSCLC without targetable aberrations and pro-
grammed death ligand 1 (PD-L1) tumor proportion score (TPS) 50%
significantly improved the primary endpoint of PFS, and OS (secondary
endpoint) compared to chemotherapy in the KEYNOTE-024 study.
In KEYNOTE-042 (NCT02220894), we evaluated pembrolizumab vs
chemotherapy at the lower PD-L1 TPS of 1%. Method: Eligible
patients were randomized 1:1 to 35 cycles of pembrolizumab 200 mg
Q3W or investigator’s choice of 6 cycles of paclitaxel + carboplatin or
pemetrexed + carboplatin with optional pemetrexed maintenance
(nonsquamous only). Randomization was stratified by region (east
Asia vs non-east Asia), ECOG PS (0 vs 1), histology (squamous vs
nonsquamous), and TPS (50% vs 1-49%). Primary endpoints were
OS in patients with TPS 50%, 20%, and 1%. OS differences
were assessed sequentially using the stratified log-rank test. Efficacy
boundaries at the prespecified second interim analysis were one-sided
P ¼ 0.0122, 0.01198, and 0.01238, respectively. Results: Overall,
1274 patients were randomized: 637 to each arm. 599 patients
(47.0%) had TPS 50%, 818 (64.2%) had TPS 20%. After a median
follow-up of 12.8-months, 13.7% were still on pembrolizumab and
4.9% were receiving pemetrexed maintenance. Pembrolizumab signif-
icantly improved OS in patients with TPS 50% (HR 0.69), TPS 20%
(HR 0.77), and TPS 1% (HR 0.81) (Table). Grade 3-5 drug-related
AEs were less frequent with pembrolizumab (17.8% vs 41.0%).
The external DMC recommended continuing the trial to evaluate
PFS (secondary endpoint). Conclusion: KEYNOTE-042 is the first
study with a primary endpoint of OS to demonstrate superiority
of pembrolizumab over platinum-based chemotherapy in patients
with previously untreated locally advanced or metastatic NSCLC
without sensitizing EGFR or ALK abberations and a PD-L1 TPS 1%.
These data confirm and potentially extend the role of pembrolizumab
monotherapy as a standard 1L treatment for PD-L1-expressing
locally advanced or metastatic NSCLC. Keywords: chemotherapy,
KEYNOTE-042, programmed death ligand 1 (PD-L1), pembrolizumabJournal of Thoracic Oncology Vol. 13 No. 9S: S152-S154PS2
CheckMate 227: Nivolumab + Ipilimumab vs
Chemotherapy as 1L Treatment for Advanced NSCLC
With High Tumor Mutational BurdenC. Mathias,1 M. Reck,2 M. Hellmann,3 S. Ramalingam,4 J. Brahmer,5
K. O’Byrne,6 P. Bhagavatheeswaran,7 F. Nathan,7 H. Borghaei,8
L. Paz-Ares9 1Nucleo De Oncologia Da Bahia, Bahia/BR, 2Lung Clinic
Grosshansdorf, Airway Research Center North (ARCN), member of the
German Center for Lung Research (DZL), Grosshansdorf/DE, 3Memorial
Sloan Kettering Cancer Center, New York, NY/US, 4Winship Cancer
Institute, Emory University, Atlanta, GA/US, 5Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD/US,
6Princess Alexandra Hospital Brisbane, Queensland, QLD/AU, 7Bristol-
Myers Squibb, Princeton, NJ/US, 8Fox Chase Cancer Center, Philadelphia,
PA/US, 9Hospital Universitario Doce de Octubre, CNIO, Universidad
Complutense & CiberOnc, Madrid/ES
Background: CheckMate 227 (NCT02477826) is a large phase 3 study
of first-line nivolumab-based regimens vs platinum-doublet chemo-
therapy in advanced non-small cell lung cancer (NSCLC). We report
results from Part 1, including a preplanned co-primary endpoint
evaluating progression-free survival (PFS) of nivolumab + ipilimumab
vs chemotherapy in patients with high tumor mutational burden
(TMB 10 mut/Mb), safety of nivolumab + low-dose ipilimumab,
and patient-reported outcomes (PROs). Method: Patients (N ¼ 1739)
with chemotherapy-naive, stage IV/recurrent NSCLC without known
sensitizing EGFR/ALK alterations were randomized 1:1:1 to nivolumab
(3 mg/kg Q2W) + ipilimumab (1 mg/kg Q6W), nivolumab mono-
therapy (240 mg Q2W), or chemotherapy for patients with 1% tumor
programmed death-ligand 1 (PD-L1) expression and to nivolumab +
ipilimumab, nivolumab (360 mg Q3W) + chemotherapy, or chemo-
therapy for patients with <1% tumor PD-L1 expression. Co-primary
endpoints were overall survival for nivolumab + ipilimumab vs
chemotherapy in patients with PD-L1eselected tumors and PFS (blin-
ded independent central review) for nivolumab + ipilimumab vs
chemotherapy in patients with high TMB 10 mut/Mb. TMB was
determined from tumor tissue using the FoundationOne CDxTM assay.
Safety analyses included time to onset and time to resolution of select
treatment-related adverse events (select TRAEs; those with a potential
immunologic cause) and corticosteroid use. PROs were assessed using
the Lung Cancer Symptom Scale and EQ-5D instruments. Results:
Minimum follow-up was 11.2 months. PFS was significantly longer with
nivolumab + ipilimumab vs chemotherapy in patients with high TMB
10 mut/Mb (HR ¼ 0.58 [97.5% CI: 0.41, 0.81]; P ¼ 0.0002); results
were consistent across subgroups, including PD-L1 expression and
tumor histology. Rates of TRAEs leading to discontinuation were
17% with nivolumab + ipilimumab and 9% with chemotherapy.
Grade 3e4 TRAEs occurred in 31% and 36% of patients treated with
